Cure8 research brief
IgA vasculitis can be a rare adverse effect of anti-TNF therapy like infliximab and may mimic Crohn’s relapse, so recognizing it can prevent incorrect escalation of IBD treatment.
Adults with Crohn’s disease on anti-TNF therapy; gastroenterologists and IBD clinicians.
The article reports a 38-year-old man with ileocolonic Crohn’s disease on infliximab who developed fever, diarrhea, severe abdominal pain, melena, and palpable purpura. Endoscopy showed duodenal ulcers; biopsies of skin and duodenal tissue confirmed leukocytoclastic vasculitis consistent with IgA vasculitis attributed to infliximab.
The authors emphasize that GI-predominant vasculitis can present before skin findings ("herald enteritis") and that biopsy of duodenal ulcers can distinguish vasculitis from Crohn’s relapse, avoiding escalation of IBD therapy.
Single case report; structured content depth is abstract from the journal article. Findings are descriptive from this patient and do not quantify risk.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
The article outlines complications that can come from Crohn’s disease, many of which may need tests, medication, or surgery. Knowing these helps you recognize warning signs and talk with your care team about prevention...
Chronic inflammation in Crohn’s, especially when the colon is affected, raises colorectal cancer risk over time. Knowing risk factors and recommended screening helps people with Crohn’s get earlier detection and...
